CMS to Reimburse for Genetic Testing in Iverson's Warfarin PGx Study; Genmark to Provide Platform
July 28, 2010
CMS to Reimburse for Genetic Testing in Iverson's Warfarin PGx Study; Genmark to Provide Platform
The CMS approval "is for a clinical study under 'coverage with evidence development' and will cover pharmacogenetic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness," Iverson Genetics said in a statement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Study Shows PGx-based Warfarin Dosing Algorithm Beats INR Alone, Even in Second Week of Treatment
March 14, 2012 / Pharmacogenomics Reporter - Georgia Governor to Proclaim Sept. 1 Personalized Medicine Awareness Day
August 17, 2011 / Pharmacogenomics Reporter - When Might Warfarin PGx Be Better Than Pradaxa? Stakeholders Weigh In
October 27, 2010 / Pharmacogenomics Reporter - New Warfarin PGx Study Will Test New Dosing Algorithms, Aim to Avoid Criticisms of Past Trials
April 14, 2010 / Pharmacogenomics Reporter - Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs
May 9, 2012 / Pharmacogenomics Reporter